IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30
iBio, Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 28, 2026
$0.76−0.01 (-0.81%)
Close on Oct 19, 2026
- Market cap
- $110.48M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
–
Operating margin
-35141.0%−33828.9 pts over 5 years
Net margin
-33044.0%−32065.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -75.0% | – | -46.9% | -20.1% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | -154.2% | -28.1% | -65.7% | |
| Return on assets | -33.2% | -19.2% | -54.0% | |
| Current ratio | 4.26 | 15.74 | 7.85 | |
| Debt to equity | – | 0.00 | – | |
| Interest coverage | -7.4× | -12.7× | -663.0× | |
| Capex to revenue | 335.8% | 207.5% | 578.0% | |
| Diluted shares | 0M | 0M | 104M |
Where the cash went
Fiscal 2022 to 2026, five years combined
iBio generated $124.99M from operations and spent $13.87M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$124.99M
Used
$13.87M
Capital expenditure$13.87M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-33044.0%
×Asset turnover0.00×
×Equity multiplier1.22×
=Return on equity, FY2026-65.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | -33044.0% | 0.00× | 1.22× | -65.7% |
| FY2025 | -4594.3% | 0.02× | 1.43× | -101.5% |
| FY2024 | -11069.8% | 0.01× | 1.91× | -135.7% |
| FY2022 | -2670.0% | 0.02× | 1.43× | -58.5% |
| FY2021 | -978.8% | 0.02× | 1.46× | -28.1% |
| FY2020 | -1003.6% | 0.03× | 2.11× | -55.6% |
| FY2019 | -871.8% | 0.05× | 3.95× | -188.9% |
| FY2018 | -3627.3% | 0.01× | 3.15× | -128.4% |
| FY2017 | -3688.3% | 0.01× | 4.65× | -154.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
2of 7 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero-$33.04M
- Cash generatingOperating cash flow above zero-$23.22M
- Return on assets improvedROA up on the prior year-64.0% → -142.5%
- Earnings backed by cashOperating cash flow above net income-$23.22M vs -$33.04M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.59 → 7.85
- No dilutionShare count did not rise10M → 104M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.01 → 0.00